Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235558 | 0.94 | CASP3 (0.30) | — | |
| SCHEMBL2235207 | 0.92 | EGFR (0.31) | ALOX5SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2236103 | 0.90 | ALOX5 (0.35) | KCNA3ALOX5GPR84MMP2MMP9 | |
| SCHEMBL2234896 | 0.89 | IKBKB (0.31) | — | |
| SCHEMBL2235177 | 0.89 | L3MBTL1 (0.30) | — | |
| SCHEMBL2234338 | 0.89 | — | — | |
| SCHEMBL2234452 | 0.89 | — | — | |
| SCHEMBL2238821 | 0.87 | — | — | |
| SCHEMBL2234235 | 0.86 | FFAR1 (0.30) | — | |
| SCHEMBL2237749 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2360163-B1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | JAPAN POLYPROPYLENE CORP (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-8461365-B2 | Metallocene complex and polymerization method of olefin | JAPAN POLYPROPYLENE CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | JAPAN POLYPROPYLENE CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2360163-A1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | Japan Polypropylene Corporation (JP) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | ALOX12, ALOX15, ALOX15B | KCNA3 3488/4885ALOX5 31/4885GPR84 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.